Clinical data through the last week of October 2022 has dropped 17% in comparison with 2021. So far in 2022, there have been a total of 2,812 phase I, II and III clinical entries, compared with 3,389 during the first 10 months of 2021.
Ernst & Young’s (EY) annual Pulse of the Industry report offers plenty of reasons for optimism within med tech as the impact of the pandemic recedes, while identifying several key areas that will require continued focus for the sector’s long-term success.
More than 15,700 employees at 101 biopharma companies have lost their jobs in 2022 as industry leaders struggle to stay afloat in an uncertain and challenging economic environment. Firms have explained the layoffs by citing everything from asset prioritization and cost-efficiency to closing plants and drug failures.
With a 52% increase in patent filings and a 160% jump in research publications, the RNA technology field has exploded in the last 10 to 12 years, and the U.S. and mainland China are paving the way. Identifying seven emerging RNA innovators, Clarivate plc’s RNA Technology Companies to Watch is a new report that harnesses data and insights from both Clarivate and BioWorld.
Approval of a new depression drug, stellar phase III data for both a schizophrenia therapy and an Alzheimer’s disease candidate, as well as an accelerated approval filing for a Duchenne muscular dystrophy gene therapy, are all reasons that BioWorld’s Neurological Diseases Index climbed from a negative position throughout much of 2022 to its 11% above-water mark as of Oct. 20.
The value of med-tech mergers and acquisitions, as well as deals, fell in the third quarter, although 2022 remains a standout year. M&As are at a five-year high, while deals are second only to 2019, in terms of overall value during the first three quarters. The volume of M&As are behind 2021, but deal volume this year remains on top.